Canada markets closed

Axonics, Inc. (AXNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
67.28+0.17 (+0.25%)
At close: 04:00PM EDT
67.28 0.00 (0.00%)
After hours: 05:29PM EDT

Axonics, Inc.

26 Technology Drive
Irvine, CA 92618
United States
949 396 6322
https://www.axonics.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees797

Key Executives

NameTitlePayExercisedYear Born
Mr. Raymond W. CohenCEO & Director1.75MN/A1959
Ms. Kari KeeseChief Financial Officer1.64M46.74k1985
Mr. Rinda K. SamaChief Operating Officer888.2kN/A1979
Dr. John Woock Ph.D.Executive VP, Chief Marketing & Strategy Officer888.2k1.51M1983
Mr. Alfred J. Ford Jr.Chief Commercial Officer909.52k1.9M1971
Mr. Guangqiang Jiang Ph.D.Chief Technology OfficerN/AN/A1974
Mr. Neil BhalodkarVice President of Investor RelationsN/AN/AN/A
Mr. Aaron PettitGeneral Counsel & Chief Compliance OfficerN/AN/AN/A
Mr. Michael V. Williamson Esq., J.D.Senior VP, General & IP CounselN/AN/A1972
Dr. Karen L. Noblett M.A.S., M.D.Chief Medical Officer651.4k897.47k1963
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Corporate Governance

Axonics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.